Severe asthma and biologics: Data are good, listening to patients is better

Published in "Annals of Allergy, Asthma & Immunology" on September 01, 2021 by Don A. Bukstein, MD and Daniel Guerra Jr.

Although economic considerations should not be the concern of clinicians, the reality of the situation is that clinicians have no choice today but to be aware of how the testing and treatments that they prescribe affect patients, especially those with a chronic illness. All segments of the health care industry should support enacting policy that limits the reimbursement of low-value services that do not meet the individual patient need. The reality is that many, if not most, low-value services reflect medical care that does not serve the patient’s best interest.